Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
j_fco-2022-0009_tab_006
| HER2-Surgery | ||||||
|---|---|---|---|---|---|---|
| HER2-0 | HER2-1 | HER2-2neg | HER2-2pos | HER2+3 | ||
| HER2-core | HER2-0 | 71.1% | 26.8% | 1.4% | 0.7% | 0.0% |
| HER2-1 | 12.9% | 66.9% | 17.3% | 1.4% | 1.4% | |
| HER2-2neg | 10.0% | 35.0% | 50.0% | 5.0% | 0.0% | |
| HER2-2pos | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | |
| HER2+2-ND | 10.0% | 20.0% | 65.0% | 5.0% | 0.0% | |
| HER2+3 | 0.0% | 13.3% | 6.7% | 20.0% | 60.0% |
j_fco-2022-0009_tab_005
| HER2-neg to HER2-pos | 7 out of 138 | 5.1% |
| HER2-0 to HER2-low | 10 out of 40 | 25.0% |
j_fco-2022-0009_tab_008
| Sarcoma type | site of primary | sex | age | stage | site of NGS | mutation | line of targeted treatment | drug | duration |
|---|---|---|---|---|---|---|---|---|---|
| ES | Big toe foot | Male | 39 | metastatic | metastasis | RAD50, BRCA2 | 4th | Olaparib | 2,5 months |
| uLPS | ampulla of Vater | Female | 77 | metastatic | metastasis | CHEK2 | 2nd | Olaparib | 1 month |
| MPNST | unknown primary tumor | Male | 48 | metastatic | metastasis | BRAF | 1st | Dabrafenib/Trametinib | 12 months |
| IFT | abdomen | Female | 68 | local | Primary tumor | ALK | 1st | crizotinib | 6 months ongoing |
| ERMS | jaw | Male | 22 | lung | metastasis | BRCA1 | 7th | olaparib | 1 month |
Clinicopathological characteristics of patients
| Median (25th–75th perc) | Missing (%) | |
|---|---|---|
| Total | 1470 | 38 (2,6%) |
| Age | 59 (18 – 94) | |
| Date of Diagnosis | 01/01/1994–30/12/2018 | |
| Stage | 1416 | 54 (3,7%) |
| I | 218 (15,4%) | |
| II | 119 (8,4%) | |
| IIIa | 39 (2,8%) | |
| IIIb | 58 (4,1%) | |
| IIIc | 774 (54,7%) | |
| IV | 208 (14,7%) | |
| Histology | 1419 | 51 (3,4%) |
| Serous | 894 (63%) | |
| Mucinous | 77 (5,4%) | |
| Clear cell | 114 (8%) | |
| Endometrioid | 163 (11,5%) | |
| Poorly differentiated | 55 (3,6%) | |
| Other | 116 (8,2%) | |
| Grade | 1224 | 246 (16,7%) |
| Low (G1) | 99 (8%) | |
| High | ||
| BRCA 1/2 mutations | 92 (6,3%) | |
| Present | 27 (29,3%) | |
| Absent | 65 (70,7%) | |
| Not tested | 1378 (93,7%) | |
| Surgery | 1463 | 7 (0,4%) |
| PDS | 1254 (85,7%) | |
| IDS | 124 (8,5%) | |
| None | 84 (5,7%) | |
| ECOG | 1340 | 130 (8,8%) |
| 0 | 891 (66,5%) | |
| I | 253 (17,2%) | |
| II | 123 (9,2%) | |
| III | 61 (4,6%) | |
| IV | 11 (0,8%) | |
| 989 | 481 (32,7%) | |
| Median PFS (months) | 37,9 | |
| Median PFS - IIIC | 27,5 | |
| Median PFS - IV | 24,63 | |
| Median PFS - IIIC/IV | 26,89 | |
| 1447 | 23 (1,6%) | |
| Median OS (months) | 52,04 | |
| Median OS - IIIC | 45,16 | |
| Median OS - IV | 31,98 | |
| Median OS – IIIC/IV | 42,36 |
j_fco-2022-0009_tab_007
| HER2-neg to HER2-pos | 7 out of 301 | 2.3% |
| HER2-0 to HER2-low | 40 out of 142 | 28.2% |
j_fco-2022-0009_tab_002
| CHEMOTHERAPY COST | COST PER PATIENT | NUMBER OF PATIENTS | COST PER SESSION | AVG No SESSIONS | AVG AGE | ΓYNAIKEΣ WOMEN | AAAAAA MEN | ||
|---|---|---|---|---|---|---|---|---|---|
| BREAST CANCER | 2007 | 1.597.695,04 € | 10.442,45 € | 153 | 1.316,06 € | 7 | 61 | 151 | 2 |
| 2016 | 1.460.909,35 € | 10.075,24 € | 145 | 1.295,13 € | 7 | 59,8 | 142 | 3 | |
| PANCREATIC CANCER | 2007 | 248.681,69 € | 5.920 € | 42 | 826,19 € | 7 | 64 | 13 | 29 |
| 2016 | 306.121,73 € | 3.327,41 € | 92 | 352,67 € | 9 | 65,5 | 43 | 49 |
j_fco-2022-0009_tab_001
| Primary tumor | Incidence | Gender (female) | Age≥65 | BMI≥30 | Smoking | Khorana score ≥2 | Metastatic | HRTAs | DDIs |
|---|---|---|---|---|---|---|---|---|---|
| Pancreas | 27.2 | 40.9 | 54.0 | 11.2 | 49.2 | 100.0 | 76.7 | 96.8 | 63.1 |
| Lung | 25.8 | 22.3 | 57.6 | 19.2 | 88.1 | 60.5 | 88.5 | 89.3 | 58.2 |
| Stomach | 7.1 | 23.8 | 57.1 | 14.3 | 61.2 | 98.0 | 65.9 | 89.8 | 32.7 |
| Urological | 11.6 | 9.5 | 66.3 | 22.5 | 71.3 | 26.3 | 69.3 | 66.3 | 47.5 |
| Rectal | 11.1 | 37.3 | 59.2 | 11.8 | 47.4 | 21.1 | 85.5 | 93.4 | 30.3 |
| Breast | 4.2 | 96.2 | 24.1 | 17.2 | 34.5 | 17.2 | 73.1 | 62.1 | 65.5 |
| Ovarian | 4.1 | 100.0 | 60.7 | 25.0 | 28.6 | 67.9 | 76.9 | 85.7 | 78.6 |
| Corpus uterus | 1.2 | 100.0 | 62.5 | 62.5 | 25.0 | 62.5 | 83.3 | 62.5 | 87.5 |
| Cervix uterus | 0.7 | 100.0 | - | - | 80.0 | 80.0 | 80.0 | 100.0 | 100.0 |
| Other | 7.0 | 32.4 | 43.8 | 29.2 | 66.7 | 4.2 | 64.7 | 83.3 | 50.0 |
j_fco-2022-0009_tab_004
| HER2-ResD | ||||||
|---|---|---|---|---|---|---|
| HER2-0 | HER2-1 | HER2-2neg | HER2-2pos | HER2+3 | ||
| HER2-core | HER2-0 | 72.5% | 22.5% | 2.5% | 0.0% | 2.5% |
| HER2-1 | 11.1% | 73.6% | 9.7% | 0.0% | 5.6% | |
| HER2-2neg | 15.4% | 42.3% | 34.6% | 3.8% | 3.8% | |
| HER2-2pos | 0.0% | 33.3% | 8.3% | 50.0% | 8.3% | |
| HER2+3 | 7.4% | 3.7% | 3.7% | 3.7% | 81.5% |